Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.
Bogden
A E
AE
Biomeasure Incorporated, Hopkinton, Massachusetts 07148.
Carde
P
P
de Paillette
E D
ED
Moreau
J P
JP
Tubiana
M
M
Frindel
E
E
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002460:Cell Line; D003520:Cyclophosphamide / Q000627:therapeutic use / Q000633:toxicity*; D003561:Cytarabine / Q000494:pharmacology / Q000633:toxicity*; D005260:Female; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000503:physiopathology; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
D006131:Growth Inhibitors; D009842:Oligopeptides; D003561:Cytarabine; D003520:Cyclophosphamide; C058504:goralatide